BGI is the world's leading genomics solutions group, with the mission to empower scientists and health professionals to improve human health conditions by providing cutting edge genomic tools. BGI Group started out at the forefront of the fight against COVID-19 in China and is now spearheading the worldwide response, deploying millions of PCR detection tests as well as emergency laboratory solutions, automated viral nucleic acid extractions and powerful sequencers to track virus mutations. In addition, over 300,000 of BGI’s test kits have been donated by BGI and partner organizations.
The Huo-Yan ('Fire Eye') Laboratory System is an all-in-one, high-throughput detection solution that brings together the best of BGI Group, combining BGI Genomics' SARS-CoV-2 testing kits, MGI’s automated RNA extraction equipment and sequencers, and the genomic skills and knowledge of scientists throughout the BGI Group. The Fire Eye lab was first created in response to the COVID-19 outbreak in Wuhan, where a 2000 m2 emergency testing lab was built in five days, to handle 10,000 COVID-19 tests daily.
A comprehensive solution for rapidly scaling up diagnostic testing, Fire Eye labs are being implemented in the US, Europe, the Middle East and Asia.
The Fire Eye laboratory equipment is produced by MGI, a part of the BGI Group focused on sequencing tools and lab automation. MGl's cutting-edge laboratory robots automate sample preparation, enabling laboratories to handle thousands of samples a day. MGl’s high-throughput genetic sequencers play a critical role in the surveillance of SARS-CoV-2 viral evolution. Sequencing allows us to understand the virus blueprint, dynamically track virus mutations and identify new strains of the virus. It can also be used to confirm results of PCR-based tests.
BGI Genomics, part of BGI Group, has developed a real-time fluorescent RT-PCR kit for detecting SARS-CoV-2, with production capacity of two million reactions a day to meet global demand. Over 10 million test kits have been produced and are being distributed to more than 80 countries. BGI’s SARS-CoV-2 test has been granted approval by the US FDA Emergency Use Authorization, Europe’s EMA, China’s NMPA, Japan’s PMDA and Australia’s TGA.
BGI Genomics Co Ltd. is one of the largest genomics organizations in the world. A division of BGI Group, BGI Genomics has over 20 years of experience serving partners in more than 66 countries, with a proven track record of innovative, high-profile research and a history of responding to global health crises.
MGI Tech Co. is democratizing access to genomics and transforming lives by developing advanced life science tools. Founded in 2016 as a division of BGI Group, MGI is a leading producer of clinical high-throughput gene sequencers, reagents, laboratory automation tools and other life science equipment.